Review article · 2018 · Open access
Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases
European Journal of Immunology, 48(5), 751–756 · Published 26 February 2018 · DOI 10.1002/eji.201747059
In brief
“Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases” is a 2018 review article by Pau Serra and Pere Santamaría, published in European Journal of Immunology. OpenAlex counts 68 citations as of 22 November 2026, which puts it in the top 6% of works published in 2018 by citations. It is open access: the full text is free to read at European Journal of Immunology.
- Citations
- 68
- Most cited in
- 2020 (13)
- Field-weighted impact
- 0.93
- References
- 34
- Authors
- 2
Abstract
Autoimmune diseases are caused by antigenically complex immune responses of the adaptive and innate immune system against specific cells, tissues or organs. Antigen-specific approaches for induction of immune tolerance in autoimmunity, based on the use of antigenic peptides or proteins, have failed to deliver the desired therapeutic results in clinical trials. These approaches, which are largely relying on triggering clonal anergy and/or deletion of defined autoreactive specificities, do not address the overwhelming antigenic, molecular, and cellular complexity of most autoimmune diseases, which involve various immune cells and ever-growing repertoires of antigenic epitopes on numerous self-antigens. Advances in the field of regulatory T-cell (Treg) biology have suggested that Treg cells might be able to afford dominant tolerance provided they are properly activated and expanded in vivo. More recently, nanotechnology has introduced novel technical advances capable of modulating immune responses. Here, we review nanoparticle-based approaches designed to induce immune tolerance, ranging from approaches that primarily trigger clonal T-cell anergy or deletion to approaches that trigger Treg cell formation and expansion from autoreactive T-cell effectors. We will also highlight the therapeutic potential and positive outcomes in numerous experimental models of autoimmunity.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Serra, P., & Santamaría, P. (2018). Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases. European Journal of Immunology, 48(5), 751–756. https://doi.org/10.1002/eji.201747059
MLA 9
Serra, Pau, and Pere Santamaría. “Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases.” European Journal of Immunology, vol. 48, no. 5, 2018, pp. 751–756. https://doi.org/10.1002/eji.201747059.
Chicago
Serra, Pau and Pere Santamaría. 2018. “Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases.” European Journal of Immunology 48 (5): 751–756. https://doi.org/10.1002/eji.201747059.
Harvard
Serra, P. and Santamaría, P. (2018) ‘Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases’, European Journal of Immunology, 48(5), pp. 751–756. doi:10.1002/eji.201747059.
IEEE
P. Serra and P. Santamaría, “Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases,” European Journal of Immunology, vol. 48, no. 5, pp. 751–756, 2018, doi: 10.1002/eji.201747059.
BibTeX
@article{serra2018nanoparticle,
title = {{Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases}},
author = {Serra, Pau and Santamaría, Pere},
journal = {European Journal of Immunology},
year = {2018},
volume = {48},
number = {5},
pages = {751--756},
doi = {10.1002/eji.201747059},
url = {https://doi.org/10.1002/eji.201747059}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2018 | 3 | |
| 2019 | 12 | |
| 2020 | 13 | |
| 2021 | 12 | |
| 2022 | 12 | |
| 2023 | 4 | |
| 2024 | 6 | |
| 2025 | 4 | |
| 2026 | 2 |
Its field-weighted citation impact is 0.93: it has been cited 0.93 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- autoimmune disease
- immune tolerance
- nanoparticles
- regulatory T cells
- T cell deletion
- autoreactive T cells
- autoantigens
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Serra, P., & Santamaría, P. (2018). Nanoparticle‐based approaches to immune tolerance for the treatment of autoimmune diseases. European Journal of Immunology, 48(5), 751–756. https://doi.org/10.1002/eji.201747059
How many times has this paper been cited?
68 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at European Journal of Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Pau Serra, Pere Santamaría.
What is the DOI of this paper?
10.1002/eji.201747059, permanently at https://doi.org/10.1002/eji.201747059. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.